All In Biotech

Drugs by condition

Drugs approved for myelodysplastic syndromes

Brand-name prescription drugs and biologics whose FDA label lists myelodysplastic syndromes as an approved use. Matched on the label phrases: "myelodysplastic".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

17

Still marketed, NDA or BLA

Drug classes

7

Novel drugs

10

New molecular entities and new biologics

In development

32

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for myelodysplastic syndromes.

  • Grafapex (Treosulfan) · Medexus NovelOrphanJan 21, 2025
  • Imkeldi (Imatinib Mesylate) · Shorla Oncology Nov 22, 2024
  • Rytelo (Imetelstat Sodium) · Geron NovelOrphanJun 6, 2024
  • Alvaiz (Eltrombopag Choline) · Teva Pharms INC Nov 29, 2023
  • Inqovi (Cedazuridine, Decitabine) · Taiho Oncology NovelPriority reviewOrphanJul 7, 2020

All approved drugs for myelodysplastic syndromes, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 63 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Nucleoside Metabolic Inhibitor (3)

  • Inqovi Cedazuridine, Decitabine · Taiho Oncology · 2020
  • Vidaza Azacitidine · Bristol-Myers · 2004
  • Azacitidine Azacitidine · Actavis LLC · 2016

Iron Chelator (3)

Erythroid Maturation Agent (1)

  • Reblozyl Luspatercept-Aamt · Celgene Corp · 2019

Isocitrate Dehydrogenase 1 Inhibitor (1)

  • Tibsovo Ivosidenib · Servier · 2018

Thrombopoietin Receptor Agonist (1)

  • Nplate Romiplostim · Amgen · 2008

Thalidomide Analog (1)

  • Revlimid Lenalidomide · Bristol Myers Squibb · 2005

Class not listed in FDA's data (7)

  • Grafapex Treosulfan · Medexus · 2025
  • Rytelo Imetelstat Sodium · Geron · 2024
  • Promacta Eltrombopag Olamine · Novartis · 2008
  • Imkeldi Imatinib Mesylate · Shorla Oncology · 2024
  • Alvaiz Eltrombopag Choline · Teva Pharms INC · 2023
  • Promacta Kit Eltrombopag Olamine · Novartis · 2015
  • Gleevec Imatinib Mesylate · Novartis · 2003

Drugs in development for myelodysplastic syndromes

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • APG-2575lisaftoclaxPhase 310 trials

    Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  • AND017Phase 36 trials

    Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia

  • ElriterceptTAK-226, KER-050Phase 36 trials

    Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia

  • BL-M11D1Phase 32 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes

  • RoxadustatFG-4592, ASP1517Phase 32 trials

    Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes

  • ASTX030cedazuridine + azacitidinePhase 31 trial

    Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm

  • RimiducidAP1903Phase 23 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • RVU120SEL120Phase 23 trials

    Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome

  • bexmarilimabFP-1305Phase 22 trials

    Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia

  • BLEX 404 LiquidPhase 22 trials

    BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer

  • DISC-0974Phase 22 trials

    Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia

  • OfirnoflastHT-6184Phase 22 trials

    Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome

  • rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

  • TebapivatAG-946Phase 22 trials

    Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease

  • AB8939Phase 21 trial

    AB Science · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia

  • ABD-3001DIMATEPhase 21 trial

    Advanced BioDesign · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes

  • ARD103Phase 21 trial

    ARCE Therapeutics, Inc. · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)

  • AZD3632Phase 21 trial

    AstraZeneca · Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

  • CFI-400945Phase 21 trial

    Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

1 discontinued brand-name drugs whose label still names it

More on myelodysplastic syndromes: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelofibrosis · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.